Form 4: Ginkgo Bioworks Insider Sells Shares for Tax Withholding

Barry Canton, a director at Ginkgo Bioworks Holdings, Inc., reported transactions involving the sale of Class A Common Stock to cover tax withholding obligations related to vested performance-based restricted stock units.

Summary

• Barry Canton, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc. (DNA), reported transactions on April 7th, 8th, and 9th, 2026.
• These transactions involved the acquisition and subsequent disposition of Class A Common Stock.
• Specifically, 27,738 shares were acquired on April 7th and 8th, 2026, related to the vesting of performance-based restricted stock units (PSUs).
• On April 8th and 9th, 2026, Canton sold a total of 26,271 shares at prices ranging from $6.397 to $6.93 to cover tax withholding obligations arising from the PSU vesting.
• The vesting of these PSUs reflected 67% of the target performance based on a company-wide cash flow reduction target for the period January 1, 2025, to December 31, 2025.
• Following these transactions, Canton beneficially owns 338,568 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves insider transactions, the sales are explicitly for tax withholding purposes related to vested equity, a common and expected event, rather than discretionary trading.

Positives

• The vesting of performance-based restricted stock units indicates that the company achieved a portion of its performance targets.
• The 'sell to cover' transactions are standard practice for covering tax liabilities upon vesting and do not necessarily indicate a negative view of the stock by the insider.

Negatives

• A portion of the insider's vested equity was sold, reducing their direct holdings.
• The performance achieved was 67% of the target, indicating that the company did not fully meet its cash flow reduction goals for the specified period.

Risks

• The company's ability to meet its cash flow reduction targets could be an ongoing concern if performance remains below expectations.
• Future tax withholding obligations could lead to further sales of company stock by insiders.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from management regarding future financial performance or strategic direction. It primarily reports on past transactions.

Management Comments

• Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders and are common across the biotechnology and synthetic biology sectors. The reporting of 'sell to cover' transactions for tax purposes is a standard mechanism for executives to manage equity compensation obligations without necessarily signaling a negative outlook on the company's stock.

Stakeholder Impact

• Shareholders: The 'sell to cover' transactions are not indicative of a negative outlook by the insider and are a standard mechanism for managing equity compensation. The actual impact on share price is likely minimal.
• Employees: The vesting of PSUs and subsequent tax handling for management reflects the company's incentive programs.
• Management: Barry Canton is managing his equity compensation and associated tax liabilities.

Next Steps

• Continued monitoring of insider transactions for any discretionary trading activity.
• Evaluation of Ginkgo Bioworks' progress towards its performance targets, particularly cash flow reduction goals.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, Insider Trading, Barry Canton, Restricted Stock Units, PSUs, Tax Withholding, Class A Common Stock, Beneficial Ownership, Securities Exchange Act